Publications, News & Events

All 5 /News 2 /Publications 3

Flagellin-induces a hypersecretory phenotype in primary human bronchial epithelial cells, presented at North America Cystic Fibrosis Conference, Orlando, October 2016

The TLR5-agonist flagellin (FLG) is the key protein component…

October 1, 2016/by admin

Pharmacological characterisation of TMEM16A regulators, presented at The 13th European Cystic Fibrosis Basic Science Conference, Pisa, Italy, March 2016

TMEM16A was recently identified as a calcium-activated chloride…

March 2, 2016/by admin

Flagellin-induces a hypersecretory phenotype in primary human bronchial epithelial cells, presented at The 13th European Cystic Fibrosis Basic Science Conference, Pisa, Italy, March 2016

A screen of microbial-derived products using a 3D model of the…

March 1, 2016/by admin

New drug discovery company announces additional funding to tackle chronic respiratory disease

Brighton, Sussex, May 20th 2015 - ENTERPRISE THERAPEUTICS Ltd,…

May 20, 2015/by admin

World class drug discovery team launches new company to tackle chronic respiratory disease

Brighton, Sussex, February 12th 2015 - ENTERPRISE THERAPEUTICS…

February 12, 2015/by admin

Enterprise is a clinical stage biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases of high unmet medical need and commercial opportunity

Scientific Strategy

Enterprise is developing muco-regulatory drugs that are expected to help respiratory patients by improving their ability to breath and reduce the number of lung infections they experience leading to a longer and more healthy life.

Learn more

Pipeline

Enterprise has developed a pipeline of novel low molecular weight compounds with first in class potential – our most advanced compounds, which target ion channels in the airway epithelium are currently in clinical trials.

Learn more

Contact Information

Enterprise Therapeutics Ltd

info@enterprisetherapeutics.com

+44 (0)1273 234667

Latest News

Enterprise Therapeutics publishes on medicinal chemistry of ETD001, a novel inhaled ENaC blocker for treatment of Cystic FibrosisNovember 19, 2024 - 9:33 am
Enterprise Therapeutics granted ‘rare pediatric disease designation’ in the US for novel cystic fibrosis investigational therapy ETD001September 26, 2024 - 3:11 pm
Enterprise Therapeutics appoints Annabella Amatulli as Head of Regulatory AffairsSeptember 11, 2024 - 9:00 am
Enterprise Therapeutics Doses First Person with Cystic Fibrosis in Phase 2 Trial for Novel Therapy ETD001July 23, 2024 - 9:00 am

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience. View our Privacy and Cookie Policy.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
local_storage_support_test	persistent	The cookie is used in context with the local-storage function in the browser. This function allows the website to load faster by pre-loading certain procedures.
PHPSESSID	Session
rc::a	persistent	This cookie is used to distinguish between humans and bots. This is beneficial for the website, in order to make valid reports on the use of their website.
rc::c	Session	This cookie is used to distinguish between humans and bots.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

Cookie	Duration	Description
__widgetsettings	persistent	This cookie is set by Twitter - The cookie allows the visitor to share content from the website on to their Twitter profile.

Statistics

Statistics or analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Cookie	Duration	Description
collect google-analytics.com	Session	Used to sen d data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels.
_ga enterprisetherapeutics.com	2 years	Registers a unique ID that is used to generate statistical data on how the visitor uses the website.
_gat enterprisetherapeutics.com	1 day	Used by Google Analytics to throttle request rate
_gid enterprisetherapeutics.com	1 day	Registers a unique ID that is used to generate statistical data on how the visitor uses the website.

Marketing

Marketing or advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.

Cookie	Duration	Description
IDE doubleclick.net	1 year	Used by Google DoubleClick to register and report the website user's actions after viewing or clicking one of the advertiser's ads with the purpose of measuring the efficacy of an ad and to present targeted ads to the user.
test_cookie doubleclick.net	1 day	Used to check if the user's browser supports cookies.
VISITOR_INFO1_LIVE	179 days	Tries to estimate the users' bandwidth on pages with integrated You Tube videos.
YSC	Session	Registers a unique ID to keep statistics of what videos from You Tube the user has seen.
yt-remote-cast-installed	Session	Stores the user's video player preferences using embedded You Tube video
yt-remote-connected-devices	persistent	Stores the user's video player preferences using embedded You Tube video
yt-remote-device-id	persistent	Stores the user's video player preferences using embedded You Tube video
yt-remote-fast-check-period	Session	Stores the user's video player preferences using embedded You Tube video
yt-remote-session-app	Session	Stores the user's video player preferences using embedded You Tube video
yt-remote-session-name	Session	Stores the user's video player preferences using embedded You Tube video
yt.innertube::nextId	persistent	Registers a unique ID to keep statistics of what videos from You Tube the user has seen.
yt.innertube::requests	persistent	Registers a unique ID to keep statistics of what videos from You Tube the user has seen.